Note 18 – Share Based Awards (Tables)
|
9 Months Ended |
Jan. 31, 2024 |
Share-Based Payment Arrangement [Abstract] |
|
[custom:ScheduleOfAssumptionsUsed1TableTextBlock] |
|
|
|
2024 |
|
|
|
2023 |
|
Exercise Price |
|
$ |
0.95
– 1.12
|
|
|
$ |
1.06
– 2.38
|
|
Stock price on date of grant |
|
|
0.95
– 1.12
|
|
|
|
1.06
– 2.38
|
|
Risk-free interest rate |
|
|
3.47
– 4.34%
|
|
|
|
3.34
– 7.52%
|
|
Dividend yield |
|
|
—
|
|
|
|
—
|
|
Expected term (years) |
|
|
6.00
– 8.25
|
|
|
|
8.25 |
|
Volatility |
|
|
242.38
– 260.22%
|
|
|
|
253.52 – 513.58%%
|
|
|
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] |
|
|
Shares |
|
Weighted-Average
Exercise Price |
|
Weighted-Average
Remaining Contractual Term |
|
Aggregate
Intrinsic Value |
Outstanding
as of April 30, 2022 |
|
|
3,694,142 |
|
|
$ |
2.17 |
|
|
|
8.56
|
|
|
|
1,407,545 |
|
Granted |
|
|
1,503,500 |
|
|
|
1.40 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
Forfeited
or expired |
|
|
(412,833 |
) |
|
|
2.67 |
|
|
|
|
|
|
|
|
|
Outstanding as of April
30, 2023 |
|
|
4,784,809 |
|
|
|
1.88 |
|
|
|
8.72
|
|
|
|
74,586 |
|
Granted |
|
|
2,541,042 |
|
|
|
1.06 |
|
|
|
|
|
|
|
|
|
Exercised |
|
|
(3,000 |
) |
|
|
0.89 |
|
|
|
|
|
|
|
|
|
Forfeited
or expired |
|
|
(643,751 |
) |
|
|
2.43 |
|
|
|
|
|
|
|
|
|
Outstanding as of January 31, 2024 |
|
|
6,679,100 |
|
|
|
1.53 |
|
|
|
7.86 |
|
|
|
— |
|
Exercisable as of January 31, 2024 |
|
|
3,575,496 |
|
|
$ |
1.86 |
|
|
|
6.31 |
|
|
$ |
— |
|
|
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] |
|
|
Shares |
|
Weighted Average Grant-Date Fair Value Per Share |
Unvested and outstanding as of April 30, 2022 |
|
|
1,083,675 |
|
|
$ |
2.59 |
|
Granted |
|
|
780,884 |
|
|
|
2.14 |
|
Vested |
|
|
(1,062,372 |
) |
|
|
2.42 |
|
Forfeited |
|
|
(21,127 |
) |
|
|
2.13 |
|
Unvested and outstanding as of April 30, 2023 |
|
|
781,060 |
|
|
|
2.44 |
|
Granted |
|
|
298,643 |
|
|
|
1.06 |
|
Vested |
|
|
(355,661 |
) |
|
|
1.94 |
|
Forfeited |
|
|
(70,656 |
) |
|
|
1.25 |
|
Unvested and outstanding as of January 31, 2024 |
|
|
653,386 |
|
|
$ |
2.14 |
|
|
Schedule of Deferred Compensation Arrangement with Individual, Share-Based Payments [Table Text Block] |
|
|
|
|
|
|
|
|
|
|
|
Three
months ended January
31,
|
|
Nine
months ended January
31,
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Operations |
|
$ |
114,425 |
|
|
$ |
181,908 |
|
|
$ |
544,046 |
|
|
$ |
566,218 |
|
Research and development |
|
|
(106,314 |
) |
|
|
170,579 |
|
|
|
168,732 |
|
|
|
524,874 |
|
Sales and marketing |
|
|
120,180 |
|
|
|
120,733 |
|
|
|
494,392 |
|
|
|
390,076 |
|
General and administrative |
|
|
457,480 |
|
|
|
315,471 |
|
|
|
1,486,532 |
|
|
|
1,309,790 |
|
Total |
|
$ |
585,771 |
|
|
$ |
788,691 |
|
|
$ |
2,693,702 |
|
|
$ |
2,790,958 |
|
|